Comparison of anti-inflammatory effects of eye drops formulations after uncomplicated cataract surgery.
anti-inflammatory effects
cataract
dexamethasone
flare
Journal
Therapeutic advances in ophthalmology
ISSN: 2515-8414
Titre abrégé: Ther Adv Ophthalmol
Pays: United States
ID NLM: 101728805
Informations de publication
Date de publication:
Historique:
received:
01
11
2019
accepted:
03
04
2020
entrez:
5
10
2020
pubmed:
6
10
2020
medline:
6
10
2020
Statut:
epublish
Résumé
The aim of this study is to compare the efficacy of different dexamethasone eye drops formulations in controlling postoperative inflammation. Cataract surgery was carried out in 72 patients (35 males) divided into two groups: group A (36 patients, mean age = 78.0 ± 5.6) received four times daily for 2 weeks a suspension containing tobramycin 0.3% mg/ml + dexamethasone 0.1% mg/ml, and group B (36 patients, mean age = 76.2 ± 6.8) a solution containing tobramycin 0.3% mg/ml + dexamethasone 0.1% mg/ml. Both groups received ofloxacin 0.5% four times daily for 7 days, and nepafenac 0.1% three times daily for 3 weeks. Best-corrected visual acuity, intraocular pressure, corneal thickness, endothelial cells count, aqueous flare and macular thickness were evaluated preoperatively and at 1 day, 15 days, 1 and 2 months. In group A, intraocular pressure, corneal thickness and aqueous humour flare values preoperatively and at the end of follow-up were 14.3 ± 1.8 and 13.2 ± 1.8 mmHg, 546.4 ± 34.6 and 539.6 ± 36.1 µm, 11.84 ± 4.44 and 13.52 ± 5.54 ph/ms, respectively, with no statistically significant difference. In group B, intraocular pressure, corneal thickness and aqueous humour flare values preoperatively and at the end of follow-up were 14.3 ± 1.5 and 13.1 ± 1.7 mmHg, 552.9 ± 37.4 and 548.1 ± 39.3 µm, 11.45 ± 4.06 and 13.73 ± 4.99 ph/ms, respectively, with no statistically significant difference. No difference was detected in the macular thickness values in the parafoveal area preoperatively and at 2 months follow-up in group A (332.18 ± 16.19 and 337.71 ± 16.33 µm) and group B (329.11 ± 18.28 and 334.37 ± 20.86 µm), respectively. The two different formulations of dexamethasone eye drops reached the same anti-inflammatory effects.
Identifiants
pubmed: 33015542
doi: 10.1177/2515841420924304
pii: 10.1177_2515841420924304
pmc: PMC7509714
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2515841420924304Informations de copyright
© The Author(s) 2020.
Déclaration de conflit d'intérêts
Conflict of interest statement: The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Références
Br J Ophthalmol. 2002 Dec;86(12):1380-4
pubmed: 12446370
Ophthalmic Res. 2012;47(2):66-80
pubmed: 21757964
J Cataract Refract Surg. 2018 Apr;44(4):429-439
pubmed: 29778106
Arch Ophthalmol. 1976 Jun;94(6):919-20
pubmed: 938282
Ophthalmology. 2002 Oct;109(10):1887-91
pubmed: 12359610
Surv Ophthalmol. 2010 Mar-Apr;55(2):108-33
pubmed: 20159228
Surv Ophthalmol. 2004 Sep-Oct;49(5):470-90
pubmed: 15325193
J Cataract Refract Surg. 2018 Jul;44(7):836-847
pubmed: 30055692
Curr Opin Ophthalmol. 2000 Dec;11(6):478-83
pubmed: 11141645
BMC Ophthalmol. 2017 Feb 20;17(1):16
pubmed: 28219426
Acta Ophthalmol Scand. 2007 Sep;85(6):598-602
pubmed: 17645424
Curr Pharm Des. 2018;24(41):4896-4902
pubmed: 30727876
Clin Exp Ophthalmol. 2019 Apr;47(3):346-356
pubmed: 30953417
Br J Ophthalmol. 2009 Jun;93(6):708-13
pubmed: 19293163
Scand J Rheumatol Suppl. 1996;102:9-21
pubmed: 8628981
Br J Ophthalmol. 1992 Nov;76(11):681-4
pubmed: 1477046
Ophthalmology. 2015 Nov;122(11):2159-68
pubmed: 26123091
Curr Eye Res. 2016 Jul;41(7):897-9
pubmed: 26580978
Eye (Lond). 1990;4 ( Pt 3):526-30
pubmed: 2209921
J Fr Ophtalmol. 2011 Dec;34(10):691-6
pubmed: 22001623